NCT04097002 - First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions

Adenocarcinoma of the Prostate

Interventions

BIOLOGICAL

ORCA-010

The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.

Trial Locations (5)

L6T 4S5

Jonathan Giddens Medicine Professional Corporation, Brampton

L7N 3V2

G. Kenneth Jansz Medicine Professional Corporation, Burlington

L8N 4A6

Research St. Joseph's - Hamilton, Hamilton

L6H 3 P1

The Fe/Male Health Centres Recruiting, Oakville

M1S 4V5

Urology and Male Infertility Clinic, Scarborough Village